Invasive group B streptococcal infections in Sweden: incidence, predisposing factors and prognosis (Q47786208)

5 February 2018

title

Invasive group B streptococcal infections in Sweden: incidence, predisposing factors and prognosis (English)

1 reference

5 February 2018

main subject

Sweden

0 references

streptococcal infection

1 reference

Mats S Dahl

1

1 reference

5 February 2018

Ingemar Tessin

series ordinal

2

1 reference

5 February 2018

Birger Trollfors

series ordinal

3

1 reference

5 February 2018

publication date

1 June 2003

1 reference

5 February 2018

International Journal of Infectious Diseases

published in

1 reference

5 February 2018

volume

7

1 reference

5 February 2018

issue

2

1 reference

5 February 2018

page(s)

113-119

1 reference

5 February 2018

Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Group B streptococci: the new challenge in neonatal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

A half century of neonatal sepsis at Yale: 1928 to 1978

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

1 reference

7 January 2021

Neonatal septicemia and meningitis in Göttingen, West Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Incidence and etiology of neonatal septicaemia and meningitis in western Sweden 1975-1986.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive group B streptococcal disease in children beyond early infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Eight-year outcome of universal screening and intrapartum antibiotics for maternal group B streptococcal carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Neonatal group B streptococcal disease in Finland: a ten-year nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Selective intrapartum anti-bioprophylaxy of group B streptococci infection of neonates: a prospective study in 2454 subsequent deliveries

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Group B streptococci during pregnancy: a comparison of two screening and treatment protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Neonatal group B streptococcal infection in South Bedfordshire, 1993-1998

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Early onset group B streptococcal neonatal infection in Oxford 1985-96.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Systemic group B streptococcal disease in neonates and young infants in Norway 1985-94.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive group B streptococcal disease in Maryland nursing home residents.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Risk factors for group B streptococcal disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive pneumococcal infections in Southwestern Sweden: a second follow-up period of 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive group B streptococcal disease: the emergence of serotype V

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive group B streptococcal disease in nonpregnant adults

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Relapsing invasive group B streptococcal infection in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Prevention of neonatal septicaemia due to group B streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990006-3

7 January 2021

10.1016/S1201-9712(03)90006-3

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

12839712

1 reference

5 February 2018